New biotechnology project to settle in Wudang

Representatives from Wudang district and Huafu Biotechnology (Jiangxi) Co held a video conference on Dec 15 to discuss project cooperation.

Wang Mingming, Party secretary of Wudang, other Wudang government officials, as well as Zhong Bingwen, CEO of Huafu Biotechnology (Jiangxi) Co, and Ceng Li, chief strategy officer of the Jiangxi enterprise, were all present during this conference.

Zhong introduced the basic situation of the cooperation project, and the participants made exchanges on matters related to the project's promotion.

Wang said that Wudang has obvious location advantages. For a long time, the medical industry there continues to develop rapidly, and the scale effect has gradually become prominent.

It is hoped that the two sides will step up planning and promote the project to be implemented in Wudang as soon as possible.

Wudang will further develop a good business environment, provide high-quality services, and help the development of local enterprises. 

It is reported that Huafu Biotechnology (Jiangxi) Co is an enterprise mainly engaged in pharmaceutical manufacturing. The company is committed to the research and development, production and sales of biotechnology products.

Its core technology has obtained patent certificates in the United States and China.

A few of their patents include spider silk, recombinant human interferon, and NMN. The company's main products include octoxin, porcine interferon, insulin, and recombinant human interferon.